Bio-Rad Laboratories (BIO) Liabilities and Shareholders Equity (2009 - 2026)

Bio-Rad Laboratories (BIO) has 18 years of Liabilities and Shareholders Equity data on file, last reported at $9.8 billion in Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity rose 1931.12% year-over-year to $9.8 billion in Q1 2026; TTM through Mar 2026 was $30.1 billion, a 196.28% increase from a year earlier, with the FY2025 full-year figure at $10.6 billion, up 12.95% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $9.8 billion, down from $10.6 billion in the prior quarter.
• Over the last five years, Liabilities and Shareholders Equity for BIO reached as high as $14.4 billion in Q1 2022 and fell as low as $600000.0 in Q4 2022.
• Historically, Liabilities and Shareholders Equity has averaged $7.4 billion across 5 years, with a median of $9.7 billion in 2025.
• Across the five-year window, Liabilities and Shareholders Equity tumbled 99.71% in 2022 and surged 82083.33% in 2023, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $600000.0 in 2022, then jumped by 82083.33% to $493.1 million in 2023, then soared by 1799.03% to $9.4 billion in 2024, then increased by 12.95% to $10.6 billion in 2025, then decreased by 7.44% to $9.8 billion in 2026.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $9.8 billion in Q1 2026, $10.6 billion in Q4 2025, and $9.7 billion in Q3 2025.